The Sigma-1 Receptor Enhances Brain Plasticity and Functional Recovery After Experimental Stroke
Overview
Authors
Affiliations
Stroke leads to brain damage with subsequent slow and incomplete recovery of lost brain functions. Enriched housing of stroke-injured rats provides multi-modal sensorimotor stimulation, which improves recovery, although the specific mechanisms involved have not been identified. In rats housed in an enriched environment for two weeks after permanent middle cerebral artery occlusion, we found increased sigma-1 receptor expression in peri-infarct areas. Treatment of rats subjected to permanent or transient middle cerebral artery occlusion with 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride, an agonist of the sigma-1 receptor, starting two days after injury, enhanced the recovery of lost sensorimotor function without decreasing infarct size. The sigma-1 receptor was found in the galactocerebroside enriched membrane microdomains of reactive astrocytes and in neurons. Sigma-1 receptor activation increased the levels of the synaptic protein neurabin and neurexin in membrane rafts in the peri-infarct area, while sigma-1 receptor silencing prevented sigma-1 receptor-mediated neurite outgrowth in primary cortical neuronal cultures. In astrocytic cultures, oxygen and glucose deprivation induced sigma-1 receptor expression and actin dependent membrane raft formation, the latter blocked by sigma-1 receptor small interfering RNA silencing and pharmacological inhibition. We conclude that sigma-1 receptor activation stimulates recovery after stroke by enhancing cellular transport of biomolecules required for brain repair, thereby stimulating brain plasticity. Pharmacological targeting of the sigma-1 receptor provides new opportunities for stroke treatment beyond the therapeutic window of neuroprotection.
Wang X, Wu S, Zuo J, Li K, Chen Y, Fan Z Commun Biol. 2025; 8(1):150.
PMID: 39890921 PMC: 11785782. DOI: 10.1038/s42003-025-07590-2.
Chaperones vs. oxidative stress in the pathobiology of ischemic stroke.
Soldatov V, Venediktov A, Belykh A, Piavchenko G, Naimzada M, Ogneva N Front Mol Neurosci. 2024; 17:1513084.
PMID: 39723236 PMC: 11668803. DOI: 10.3389/fnmol.2024.1513084.
Manufacturing Uniform Cerebral Organoids for Neurological Disease Modeling and Drug Evaluation.
Hong H, Jun Y, Yoon S, Park S, Lee J, Jang J Biomater Res. 2024; 28:0104.
PMID: 39507522 PMC: 11538552. DOI: 10.34133/bmr.0104.
Treatment of Stroke at a Delayed Timepoint with a Repurposed Drug Targeting Sigma 1 Receptors.
Schreihofer D, Dalwadi D, Kim S, Metzger D, Oppong-Gyebi A, Das-Earl P Transl Stroke Res. 2023; 15(6):1035-1049.
PMID: 37704905 DOI: 10.1007/s12975-023-01193-x.
Astrocytes in functional recovery following central nervous system injuries.
Alhadidi Q, Bahader G, Arvola O, Kitchen P, Shah Z, Salman M J Physiol. 2023; 602(13):3069-3096.
PMID: 37702572 PMC: 11421637. DOI: 10.1113/JP284197.